Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total value of $205,050.00. Following the transaction, the insider directly owned 26,250 shares in the company, valued at $717,675. This represents a 22.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $28.02, for a total value of $210,150.00.

Maze Therapeutics Price Performance

Shares of NASDAQ MAZE opened at $26.92 on Friday. The firm has a market capitalization of $1.49 billion, a P/E ratio of -10.64 and a beta of 2.14. Maze Therapeutics, Inc. has a one year low of $12.81 and a one year high of $53.65. The company’s fifty day moving average is $27.36 and its two-hundred day moving average is $34.05. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. Analysts forecast that Maze Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP acquired a new stake in shares of Maze Therapeutics during the 1st quarter worth about $917,000. Bank of America Corp DE raised its position in shares of Maze Therapeutics by 961.3% in the first quarter. Bank of America Corp DE now owns 195,084 shares of the company’s stock valued at $5,823,000 after buying an additional 176,703 shares during the last quarter. Royal Bank of Canada raised its position in shares of Maze Therapeutics by 214.1% in the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock valued at $61,000 after buying an additional 1,383 shares during the last quarter. Exome Asset Management LLC purchased a new position in shares of Maze Therapeutics during the first quarter valued at approximately $2,642,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Maze Therapeutics by 111.3% during the first quarter. The Manufacturers Life Insurance Company now owns 14,570 shares of the company’s stock valued at $435,000 after buying an additional 7,673 shares during the period.

Analysts Set New Price Targets

A number of brokerages have issued reports on MAZE. Truist Financial dropped their target price on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, April 14th. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.